Program
AXT-1003
A development code. Also written as “AXT-1003, Enzalutamide”.
Its studies are mostly in Lymphoma, Non-Hodgkin, led by Axter Therapeutics (Beijing).
Furthest: phase 1, since Jul 12, 20233 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Axter Therapeutics (Beijing) | 32 open or running | phase 1since Jul 12, 2023 | Jul 12, 2023 | Mar 2027phase 1 · NCT06484985 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 12, 2023First study: phase 1 study in RecurrenceFirst studyNCT05965505 · 1 enrolled · China
- Jun 26, 2024Phase 1 study in Lymphoma, Non-HodgkinNCT06484985 · 78 planned · China
- Oct 8, 2026Phase 1 study in mCRPCNCT07897071 · 105 planned · China
Ahead
- Mar 2027Primary completion: phase 1 study in Lymphoma, Non-HodgkinNCT06484985
- Aug 2028Primary completion: phase 1 study in mCRPCNCT07897071
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07897071mCRPC · China | 1 | Recruiting | Aug 2028 | 105 |
| NCT06484985Lymphoma, Non-Hodgkin · China | 1 | Recruiting | Mar 2027 | 78 |
| NCT05965505Recurrence · China | 1 | Terminated | Sep 5, 2023 | 1 |
How it is read
Names in the registry
- “AXT-1003, Enzalutamide”, 2 entries
- “AXT-1003”, 2 entries
Codes read as this program: AXT1003.
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.